Last updated 2 months ago

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

224 patients around the world
Available in Argentina, United States
This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD. The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.
Novartis Pharmaceuticals
224Patients around the world

This study is for people with

Dermatitis
Atopic dermatitis

Requirements for the patient

To 100 Years
All Gender

Medical requirements

Able and willing to sign the informed consent.
Patients with a diagnosis of AD and onset of disease for at least 1 year.
Moderate to severe AD.
Participants with a clinically significant medical condition or infectious disease specified in sub-protocol.
Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG.
Participant with any other active inflammatory skin disease.
Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study.
Participants with any clinically unstable disease states that would likely require systemic corticosteroids.
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy